glenn1919
1 mes hace
CNTX,,,,,,,,,,,,,,,,,,,,,,,https://stockcharts.com/h-sc/ui?s=CNTX&p=W&b=5&g=0&id=p86431144783
Biorat
1 año hace
Updated Information
Should Investors Be Buying Context Therapeutics (CNTX)?
(Take a look at CONTEXT Therapeutics) CTIM-76 a CLDN6 antagonist that's in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This selective binding allows CTIM-76 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months. The upcoming Society for Immunotherapy of Cancer meeting may alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize CTIM-76 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trials start showing their results be prepared to pony up for shares. There is now an opportunity to invest in CNTX before the bulk of investors come up to speed concerning the potential market value of a pending CTIM-76 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain shareholder excitement as well. Currently they are on the back burner due to prioritization.
Onapristine is one example of an iron in the fire even if it seems to be on hold for now.
As stated by Context Therapeutics they will "explore strategic options for Onapristine-XR." This leaves the possibility of a joint venture concerning Onapristine or sale of Onapristine outright. Due to elevated liver function tests identified in three patients, including in one patient who discontinued treatment, although NONE of the elevated LFTs were considered serious adverse events. The Company determined that significant incremental program costs and delays were likely to be required. Context is a small entity. Cost is the reason the Oath trial is on hold not a failure.
Investors should look up the Onapristine ER trial (Oath) in the Journal of Clinical Oncology.
Why the focus is on CTIM-76 vs Onapristine even though Onapristine has value? The company see's a better path.
It's been found that CTIM-76 is more specific at binding to the desired target CLDN6 than Amgen's candidate AMG 794 Therefore it's possible CTIM-76 gets a collaboration offer or buyout offer that's large. Amgen knows it & here's why. CTIM-76 is found to be approximately 28 times more potent than a competing approach utilizing a bispecific T-cell engager (BITE) format. Don't overlook; Astellas acquired Ganymed & gains access to mAbs targeting CLDN6 (IMAB027) & CLDN18.2 (IMAB362)... CTIM-76 is thought to have more value in treating cancers.
Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that the forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Like other biotech stocks, share value tends to get heated early when showing potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different; it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened.
Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share. ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to Viking Therapeutics it had the same beat down before running up to over $25 a share. In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to break out and run to $24.27 on June 4, 2023. Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beatdown has occurred and when the facts on the ground for that investment have not changed. If you have invested that way you have better odds at picking a winner.
Concerning the science, CLDN6 differs from other claudins in that it's present in a mothers womb during a baby's development. After development CLDN6 is turned off. Cancer turns back on this claudin 6 to grow. CTIM-76 in development by CONTEXT Therapeutics attacks the turned on CLDN6. CTIM-76 is very specific at targeting CLND6. Other claudins exist that are needed in the body and targeting them could be harmful such as claudin 9 that is needed for hearing.
This isn't anything other than my own research and investors must do their own before making a wise decision.
Biorat
1 año hace
Should Investors Be Buying Context Therapeutics (CNTX)?
(Take a look at CONTEXT Therapeutics) CTIM-76 a CLDN6 antagonist that's in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This selective binding allows CTIM-76 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months. The upcoming Society for Immunotherapy of Cancer meeting may alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize CTIM-76 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trials start showing their results be prepared to pony up for shares. There is now an opportunity to invest in CNTX before the bulk of investors come up to speed concerning the potential market value of a pending CTIM-76 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain shareholder excitement as well. Currently they are on the back burner due to prioritization.
One such example investors should look up is the Onapristine ER trial (Oath) in the Journal of Clinical Oncology. Oath trial
Below is why the focus is on CTIM-76 vs Onapristine even though it has value
It's been found that CTIM-76 is more specific @ binding to the desired target CLDN6 than Amgen's candidate AMG 794 Therefore it's possible CTIM-76 gets a collaboration offer or buyout offer that's large. Amgen knows it & here's why. CTIM-76 is found to be approximately 28 times more potent than a competing approach utilizing a bispecific T-cell engager (BITE) format. Don't overlook; Astellas acquired Ganymed & gains access to mAbs targeting CLDN6 (IMAB027) & CLDN18.2 (IMAB362)... CTIM-76 is thought to have more value in treating cancers.
Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that the forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Like other biotech stocks, share value tends to get heated early when showing potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different; it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened.
Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share. ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to Viking Therapeutics it had the same beat down before running up to over $25 a share. In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to break out and run to $24.27 on June 4, 2023. Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beatdown has occurred and when the facts on the ground for that investment have not changed. If you have invested that way you have better odds at picking a winner.
Concerning the science, CLDN6 differs from other claudins in that it's present in a mothers womb during a baby's development. After development CLDN6 is turned off. Cancer turns back on this claudin 6 to grow. CTIM-76 in development by CONTEXT Therapeutics attacks the turned on CLDN6. CTIM-76 is very specific at targeting CLND6. Other claudins exist that are needed in the body and targeting them could be harmful such as claudin 9 that is needed for hearing.
This isn't anything other than my own research and investors must do their own before making a wise decision.
Biorat
1 año hace
Whether It’s Cloudy Or Sunny, You Should Be Buying Context Therapeutics (CNTX)
Oct. 3, 2023 4:39 PM ET| About: Context Therapeutics Inc. (CNTX), Includes: VKTX
Biotech Rat
Value, Special Situations, Momentum, Long/Short Equity
Summary
CTIM-76, a CLDN6 antagonist developed by Context Therapeutics, shows promise in redirecting T-cell activation towards tumor cells, enhancing safety.
The upcoming Society for Immunotherapy of Cancer meeting may highlight CTIM-76 as a potential blockbuster, leading to a surge in CNTX shares.
Analysts predict a conservative $4 a share or 164.90% increase in CNTX stock within 12 months, with a more realistic target range of $6.25-$15 explained here.
(Take a look at CONTEXT Therapeutics) CTIM-76 a CLDN6 antagonist that's in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This selective binding allows CTIM-76 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months. The upcoming Society for Immunotherapy of Cancer meeting may alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize CTIM-76 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trials start showing their results be prepared to pony up for shares. There is now an opportunity to invest in CNTX before the bulk of investors come up to speed concerning the potential market value of a pending CTIM-76 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain shareholder excitement as well.
One such example is the strategic Partnership with Tyligand Biosciences for Onapristone extended release (ONA-XR) intended for use in hormone-driven breast, ovarian, and endometrial cancer. The partnership seems to be going according to pan. For immediate refresher see the following link. Tyligand Bioscience and Context Therapeutics Sign Strategic Development Agreement for Onapristone ER
Here is a link to the Onapristine ER trial (Oath) in the Journal of Clinical Oncology. Oath trial
Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that the forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Like other biotech stocks, share value tends to get heated early when showing potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different; it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened.
Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share. ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to Viking Therapeutics it had the same beat down before running up to over $25 a share. In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to break out and run to $24.27 on June 4, 2023. Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beatdown has occurred and when the facts on the ground for that investment have not changed. If you have invested that way you have better odds at picking a winner.
Concerning the science, CLDN6 differs from other claudins in that it's present in a mothers womb during a baby's development. After development CLDN6 is turned off. Cancer turns back on this claudin 6 to grow. CTIM-76 in development by CONTEXT Therapeutics attacks the turned on CLDN6. CTIM-76 is very specific at targeting CLND6. Other claudins exist that are needed in the body and targeting them could be harmful such as claudin 9 that is needed for hearing.
Analyst's Disclosure: I/we have a beneficial long position in the shares of CNTX either through stock ownership, options, or other derivatives.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.
Looking at the Context Therapeutics 5 year chart allows for a quick snapshot of the beginning turnaround in the share price .
Biorat
1 año hace
Whether It’s Cloudy Or Sunny, You Should Be Buying Context Therapeutics (CNTX)
Oct. 3, 2023 4:29 PM ET| About: Context Therapeutics Inc. (CNTX), Includes: VKTX
Biotech Rat
Value, Special Situations, Momentum, Long/Short Equity
Summary
CTIM-76, a CLDN6 antagonist developed by Context Therapeutics, shows promise in redirecting T-cell activation towards tumor cells, enhancing safety.
The upcoming Society for Immunotherapy of Cancer meeting may highlight CTIM-76 as a potential blockbuster, leading to a surge in CNTX shares.
Analysts predict a conservative $4 share price or 164.90% increase in CNTX stock within 12 months, with a more realistic target range of $6.25-$15 explained here.
(Take a look at CONTEXT Therapeutics) CTIM-76 a CLDN6 antagonist that's in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CTIM-76 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months. That's because the upcoming Society for Immunotherapy of Cancer meeting may alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize CTIM-76 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trials start showing their results be prepared to pony up for shares. There is now an opportunity to invest in CNTX before the bulk of investors come up to speed concerning the potential market value of a pending CTIM-76 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain shareholder excitement as well. One example being onapristone extended release (ONA-XR) for use in hormone-driven breast, ovarian, and endometrial cancer. Stay tuned for updates on the robust pipeline as fact checking is near completion. CNTX shares have been beaten down just like the shares of Viking Therapeutics (VKTX) had been before running up to over $25 a share.
Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that the forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Like other biotech stocks, share value tends to get heated early when showing potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different; it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened.
Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share. ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to Viking Therapeutics it had the same beat down before running up to over $25 a share. In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to break out and run to $24.27 on June 4, 2023. Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beatdown has occurred and when the facts on the ground for that investment have not changed. If you have invested that way you have better odds at picking a winner.
Concerning the science, CLDN6 differs from other claudins in that it's present in a mothers womb during a baby's development. After development CLDN6 is turned off. Cancer turns back on this claudin 6 to grow. CTIM-76 in development by CONTEXT Therapeutics attacks the turned on CLDN6. CTIM-76 is very specific at targeting CLND6. Other claudins exist that are needed in the body and targeting them could be harmful such as claudin 9 that is needed for hearing.
Due your own research and the wise will likely agree.
Disclosure: No recommendation or advice is being given as to whether any investment is suitable for a particular investor.
Biorat
1 año hace
Whether It’s Cloudy Or Sunny, You Should Be Buying Context Therapeutics (CNTX)
(Take a look at CONTEXT Therapeutics) CTIM-76 a CLDN6 antagonist that's in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CTIM-76 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months. That's because the upcoming Society for Immunotherapy of Cancer meeting may alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize CTIM-76 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trials start showing their results be prepared to pony up for shares. There is now an opportunity to invest in CNTX before the bulk of investors come up to speed concerning the potential market value of a pending CTIM-76 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain shareholder excitement as well. One example being onapristone extended release (ONA-XR) for use in hormone-driven breast, ovarian, and endometrial cancer. Stay tuned for updates on the robust pipeline as fact checking is near completion. CNTX shares have been beaten down just like the shares of Viking Therapeutics (VKTX) had been before running up to over $25 a share.
Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that the forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Like other biotech stocks, share value tends to get heated early when showing potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different; it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened.
Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share. ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to Viking Therapeutics it had the same beat down before running up to over $25 a share. In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to break out and run to $24.27 on June 4, 2023. Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beatdown has occurred and when the facts on the ground for that investment have not changed. If you have invested that way you have better odds at picking a winner.
Concerning the science, CLDN6 differs from other claudins in that it's present in a mothers womb during a baby's development. After development CLDN6 is turned off. Cancer turns back on this claudin 6 to grow. CTIM-76 in development by CONTEXT Therapeutics attacks the turned on CLDN6. CTIM-76 is very specific at targeting CLND6. Other claudins exist that are needed in the body and targeting them could be harmful such as claudin 9 that is needed for hearing.
Due your own research and the wise will likely agree.
Biorat
1 año hace
Whether It’s Cloudy Or Sunny, You Should Be Buying Context Therapeutics (CNTX)
(Take a look at CONTEXT Therapeutics) CTIM-76 a CLDN6 antagonist is in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CTIM-76 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months given the upcoming Society for Immunotherapy of Cancer meeting could alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize claudin 6 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trails start showing their results be prepared to pony up for shares. There is opportunity to get in before the bulk of investors learn the potential market value of a pending CTIM-76 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain share holder excitement as well. One example being onapristone extended release (ONA-XR) for use in hormone-driven breast, ovarian, and endometrial cancer. Stay tuned for updates on the robust pipeline as fact checking is near completion. CNTX shares have been beaten down just like the shares of Viking Therapeutics (VKTX) had been before running up to over $25 a share.
Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Things tend to get heated early with real potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened.
Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share. ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to Viking Therapeutics it had the same beat down before running up to over $25 a share. In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to breakout and run to $24.27 on June 4, 2023. Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beat down has occurred and when the facts on the ground have not changed. If you have done that you have better odds at a winner.
Concerning the science, CLDN6 differs from other claudins in that it's present in a mothers womb during a babies development. After development CLDN6 is turned off. Cancer turns back on this claudin 6 to grow. CTIM-76 in development by CONTEXT Therapeutics attacks the turned on CLDN6. CTIM-76 is very specific at targeting CLND6. Other claudins exist that are needed in the body and targeting them could be harmful such as claudin 9 that is needed for hearing.
Due your own research and the wise will should agree.
Biorat
1 año hace
Whether It’s Cloudy Or Sunny, You Should Be Buying Context Therapeutics (CNTX)
(Take a look at CONTEXT Therapeutics) CTIM-76 a CLDN6 antagonist is in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CTIM-76 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6.25-$15 a share is reasonable within 12 months given the upcoming Society for Immunotherapy of Cancer meeting could alert investors to a potential blockbuster. CNTX shares could easily climb multiples higher given the tightly held float. By the time investors realize claudin 6 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trails start showing their results be prepared to pony up for shares. There is opportunity to get in before the bulk of investors learn the potential market value of a pending CTIM-76 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain share holder excitement as well. Stay tuned for updates on the pipeline as fact checking is near completion. CNTX shares have been beaten down just like the shares of Viking Therapeutics (VKTX) had been before running up to over $25 a share.
Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that forecast is far to conservative with a $6.25-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Things tend to get heated early with real potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different it's poised for the same type of breakout. Those Looking at the 5 year chart will have their eyes opened.
Investors should not forget Context Therapeutics announced on December 6, 2021 it had closed a previously announced placement of 5 million shares at a price of $6.25 per share. ThinkEquity acted as the sole placement agent and had no problem finding placement of those shares. There's a reason for that and that reason has not changed. The beat down of the share price is now over and referring back to Viking Therapeutics it had the same beat down before running up to over $25 a share. In fact on September 16, 2018 VKTX shares traded at $18.20 at the close of the day before being beaten down to $2.23 a share on June 5, 2022 only to breakout and run to $24.27 on June 4, 2023. Even before that on July 30, 2017 VKTX shares closed at a mere 98 cents. The proven way to invest is buying in after the beat down has occurred and when the facts on the ground have not changed. If you have done that you have better odds at a winner.
Concerning the science, CLDN6 differs from other claudins in that it's present in a mothers womb during a babies development. After development CLDN6 is turned off. Cancer turns back on this claudin 6 to grow. CTIM-76 in development by CONTEXT Therapeutics attacks the turned on CLDN6. CTIM-76 is very specific at targeting CLND6. Other claudins exist that are needed in the body and targeting them could be harmful such as claudin 9 that is needed for hearing.
Due your own research and the wise will should agree.
Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
tw0122
1 mes hace
Monksdream
5 meses hace
PonkenPlonken
7 meses hace
BooDog
2 años hace
cash4
2 años hace
Daytrader2013
2 años hace
TheFinalCD
2 años hace
Imott
2 años hace
Hercules1
2 años hace
surf1944
2 años hace
Hot Features
Premium
